




Supplemental figure 1. EZH2 mRNA levels did not correlate with the modified Rodnan skin score.




Supplemental figure 2. DZNep dose-dependently reduced the expression of EZH2 and H3K27me3 in SSc fibroblasts.




Supplemental figure 3. GSK126 significantly inhibited wound closure in SSc fibroblasts at 10 μM compared to untreated cells (NT). Experiments were performed in 2 patient cell lines with 6 replicates in each condition. The figure is representative from one patient cell line. Data was presented as mean \pm SEM.




Supplemental figure 4. GSK126 prevented skin fibrosis in the bleomycin-skin fibrosis model in mice as indicated by hydroxyproline content and measurement of the dermal thickness. Data are presented as mean \pm SD.




Supplemental figure 5. EZH2 inhibitors GSK126 and DZNep reduced H3K27me3 levels in the bleomycin-skin fibrosis model in mice.




PBS




Bleomycin+Vehicle




Bleomycin+GSK126 (0.5mg/kg)




Bleomycin+GSK126 (5mg/kg)



PBS




Bleomycin+Vehicle



Bleomycin+DZNep

Supplemental figure 6. Relative mRNA expression of genes involved in Notch signaling in normal and SSc ECs. Data are expressed as fold change compared to mean of normal ECs.



Supplemental figure 7. Relative mRNA expression levels of genes involved in Notch signaling after EZH2 inhibition by DZNep (5μM, 48 hours) in SSc fibroblasts. Data are expressed as fold change compared to PBS-treated cells. ND=not detected.

